WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524447
CAS#: 176960-47-7
Description: BMS-193884 is an oral endothelin antagonist for the potential treatment of congestive heart failure (CHF) and pulmonary hypertension.
Hodoodo Cat#: H524447
Name: BMS-193884
CAS#: 176960-47-7
Chemical Formula: C20H17N3O4S
Exact Mass: 395.09
Molecular Weight: 395.430
Elemental Analysis: C, 60.75; H, 4.33; N, 10.63; O, 16.18; S, 8.11
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BMS-193884; BMS 193884; BMS193884.
IUPAC/Chemical Name: N-(3,4-dimethylisoxazol-5-yl)-4'-(oxazol-2-yl)-[1,1'-biphenyl]-2-sulfonamide
InChi Key: LJGUZUROJOJEMI-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H17N3O4S/c1-13-14(2)22-27-19(13)23-28(24,25)18-6-4-3-5-17(18)15-7-9-16(10-8-15)20-21-11-12-26-20/h3-12,23H,1-2H3
SMILES Code: O=S(C1=CC=CC=C1C2=CC=C(C3=NC=CO3)C=C2)(NC4=C(C)C(C)=NO4)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 395.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Dhaun N, Strachan FE, Newby DE, Johnston NR, Ford NF, Hammett JL, Palmisano M, Webb DJ. Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men. Br J Clin Pharmacol. 2005 Dec;60(6):611-22. PubMed PMID: 16305585; PubMed Central PMCID: PMC1884878.
2: Humphreys WG, Obermeier MT, Barrish JC, Chong S, Marino AM, Murugesan N, Wang-Iverson D, Morrison RA. Application of structure-metabolism relationships in the identification of a selective endothelin A antagonist, BMS-193884, with favourable pharmacokinetic properties. Xenobiotica. 2003 Nov;33(11):1109-23. PubMed PMID: 14660175.
3: De Smet HR, Menadue MF, Oliver JR, Phillips PA. Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats. Clin Exp Pharmacol Physiol. 2003 Apr;30(4):278-83. PubMed PMID: 12680847.
4: Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl] - 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem. 2003 Jan 2;46(1):125-37. PubMed PMID: 12502366.
5: Murugesan N, Tellew JE, Gu Z, Kunst BL, Fadnis L, Cornelius LA, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Panchal B, Valentine MT, Chong S, Morrison RA, Carlson KE, Powell JR, Moreland S, Barrish JC, Kowala MC, Macor JE. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem. 2002 Aug 29;45(18):3829-35. PubMed PMID: 12190306.
6: Hulpke-Wette M, Buchhorn R. BMS-193884 and BMS-207940 Bristol-Myers Squibb. Curr Opin Investig Drugs. 2002 Jul;3(7):1057-61. Review. PubMed PMID: 12186267.
7: Murugesan N, Gu Z, Stein PD, Spergel S, Bisaha S, Liu EC, Zhang R, Webb ML, Moreland S, Barrish JC. Biphenylsulfonamide endothelin receptor antagonists. Part 3: structure-activity relationship of 4'-heterocyclic biphenylsulfonamides. Bioorg Med Chem Lett. 2002 Feb 25;12(4):517-20. PubMed PMID: 11844662.
8: Kim NN, Dhir V, Azadzoi KM, Traish AM, Flaherty E, Goldstein I. Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction. J Androl. 2002 Jan-Feb;23(1):76-83. PubMed PMID: 11780926.
9: Miyauchi T, Sato R, Sakai S, Kobayashi T, Ueno M, Kondo H, Kawano S, Goto K, Yamaguchi I. Endothelin-1 and right-sided heart failure in rats: effects of an endothelin receptor antagonist on the failing right ventricle. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S327-30. PubMed PMID: 11078411.
10: Sakai S, Miyauchi T, Hara J, Goto K, Yamaguchi I. Hypotensive effect of endothelin-1 via endothelin-B-receptor pathway on pulmonary circulation is enhanced in rats with pulmonary hypertension. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S95-8. PubMed PMID: 11078347.
11: Murugesan N, Gu Z, Stein PD, Spergel S, Mathur A, Leith L, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Morrison RA, Webb ML, Moreland S, Barrish JC. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists. J Med Chem. 2000 Aug 10;43(16):3111-7. PubMed PMID: 10956219.
12: Phillips PA. Interaction between endothelin and angiotensin II. Clin Exp Pharmacol Physiol. 1999 Jul;26(7):517-8. PubMed PMID: 10405777.
13: Saad D, Mukherjee R, Thomas PB, Iannini JP, Basler CG, Hebbar L, O SJ, Moreland S, Webb ML, Powell JR, Spinale FG. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure. J Am Coll Cardiol. 1998 Nov 15;32(6):1779-86. PubMed PMID: 9822109.
